Burden of Illness and Treatment Patterns for Patients with Fibromyalgia

Pain Medicine (United States)

Volumn 13, Issue 10, 2012, Pages 1366-1376

  Robinson, Rebecca L ^a   Kroenke, Kurt ^b,c,d   Mease, Philip ^e,f   Williams, David A ^g   Chen, Yi ^h   D'Souza, Deborah ⁱ   Wohlreich, Madelaine ^a   McCarberg, Bill ^j  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c REGENSTRIEF INSTITUTE   (United States)

^d VA HSR and D Center for Implementing Evidence Based Practice   (United States)

^e Seattle Rhumatology Associates   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h PharmaNet/i3   (United States)

ⁱ PharmaNet/i3   (United States)

^j KAISER PERMANENTE   (United States)

more..

Author keywords

Duloxetine; Fibromyalgia; Milnacipran; Observational; Pregabalin

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIVIRUS AGENT; BENZODIAZEPINE; CYCLOBENZAPRINE; DESVENLAFAXINE; DULOXETINE; GABAPENTIN; LIDOCAINE; MILNACIPRAN; MIRTAZAPINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; VENLAFAXINE;

ACUPUNCTURE; ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CHIROPRACTIC; COGNITIVE THERAPY; CRYOTHERAPY; EXERCISE; FEEDBACK SYSTEM; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HEALTH CARE UTILIZATION; HUMAN; HYPNOSIS; MAJOR CLINICAL STUDY; MALE; MASSAGE; MEDITATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PATIENT CARE; PHYSICIAN; PROSPECTIVE STUDY; PUERTO RICO; QUESTIONNAIRE; REFLEXOLOGY; REIKI; SPINE SURGERY; TELECONSULTATION; TRANSCUTANEOUS NERVE STIMULATION; UNITED STATES;

EID: 84867640853     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01475.x     Document Type: Article

References (40)

1. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-9.
2. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain 2006;124:117-25.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
4. Ackenheil M. Genetics and pathophysiology of affective disorders: Relationship to fibromyalgia. Z Rheumatol 1998;5(suppl 2):5-7.
5. Bogetto F, Bonatto Revello R, Bertoli C, etal. Fibromyalgia. Psychopathologic aspects. Minerva Psichiatr 1999;40:129-38.
6. Cathébras P, Lauwers A, Rousset H. Fibromyalgia. A critical review. Ann Med Interne (Paris) 1998;149:406-14.
7. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363-7.
8. Juhl JH. Fibromyalgia and the serotonin pathway. Altern Med Rev 1998;3:367-75.
9. Korszun A. Sleep and circadian rhythm disorders in fibromyalgia. Curr Rheumatol Rep 2000;2:124-30.
10. Moldofsky H. Sleep, neuroimmune and neuroendocrine functions in fibromyalgia and chronic fatigue syndrome. Adv Neuroimmunol 1995;5:39-56.
11. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome: A systematic review. Eur J Pain 2010;14:5-10.
12. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27. doi: 10.1186/1471-2474-8-27.
13. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
14. Jones KD, Liptan GL. Exercise interventions in fibromyalgia: Clinical applications from the evidence. Rheum Dis Clin North Am 2009;35:373-91.
15. Mease PJ, Choy EH. Pharmacotherapy of fibromyalgia. Rheum Dis Clin North Am 2009;35:359-72.
16. Russell IJ. Fibromyalgia syndrome: Approach to management. Prim Psychiatry 2006;13:76-84.
17. Burckhardt CS, Goldenberg DL, Crofford LJ, etal. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society (APS); 2005.
18. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2007;21:499-511.
19. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94.
20. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508.
21. Robinson RL, Birnbaum HG, Morley MA, etal. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25.
22. White LA, Birnbaum HG, Kaltenboeck A, etal. Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24.
23. Mease P, Arnold LM, Bennett R, etal. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-25.
24. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18:728-33.
25. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
26. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95.
27. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258-66.
28. O'Malley PG, Jones DL, Feuerstein IM, Taylor AJ. Lack of correlation between psychological factors and subclinical coronary artery disease. N Engl J Med 2000;343:1298-304.
29. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure of assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166:1092-7.
30. Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr Ann 2002;32:508-15.
31. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
32. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
33. Fava M, Graves LM, Benazzi F, etal. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006;67:1754-9.
34. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
35. Perrot S, Winkelmann A, Dukes E, etal. Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract 2010;64:1100-8.
36. White LA, Robinson RL, Yu AP, etal. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain 2009;10:976-83.
37. Sanchez RJ, Uribe C, Li H, etal. Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr Med Res Opin 2011;27:663-71.
38. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract 2011;11:204-16.
39. Arnold LM, Crofford LJ, Mease PJ, etal. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20.
40. Roy-Byrne PP, Sherbourne CD, Craske MG, etal. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54:327-32.